Biosimilar medicines are manufactured, distributed and monitored according to the same standards as other medicines1. In line with all other medicinal products, biosimilar medicines are permanently monitored post approval, to ensure continued safety and efficacy5. Robust pharmacovigilance activities, including routine pharmacovigilance procedures and additional specific monitoring detailed in a Risk Management Plan (RMP), ensure patient safety data is captured and examined on an ongoing basis5.
At Juno, our goal is twofold: increase patient access to high quality, lifesaving medicines and increase value within the Australian healthcare system.
Biosimilars and interchangeable biologic products present an opportunity to patients, healthcare professionals and the government, by providing increased patient access to therapies, whilst helping maintain the long-term viability and financial sustainability of the Australian and New Zealand healthcare systems.
We believe that we have the right expertise and strategies to effectively partner with biologic developers whose brands are reaching their patent expiry, plus biosimilar developers with plans to launch in Australia and New Zealand.
Post marketing surveillance
